Reply to “Allergic contact dermatitis to topical brimonidine tartrate gel 0.33% for treatment of rosacea” - 17/09/14
Doi : 10.1016/j.jaad.2014.06.040
Le texte complet de cet article est disponible en PDF.
| Funding sources: None. |
|
| Disclosure: Dr Del Rosso has served on advisory boards for Allergan, Galderma, Bayer, Medicis, Valeant, Promius, Obagi, and Ranbaxy; he has served as a consultant for Allergan, Dermira, Galderma, Bayer, Medicis, Valeant, Promius, Primus, Eisai, Unilever, Obagi, Ranbaxy, and Taro Pharma; he is a speaker for Allergan, Bayer, Galderma, Medicis, Valeant, Promius, Unilever, Warner-Chilcott, Obagi, and Ranbaxy; he has served as an investigator for Allergan, Galderma, and Medicis; and he has received honoraria as compensation. |
© 2014
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 71 - N° 4
P. 833-834 - octobre 2014 Retour au numéro
Article précédent
- Allergic contact dermatitis to topical brimonidine tartrate gel 0.33% for treatment of rosacea
- Leah A. Swanson, Erin M. Warshaw
- Excision of melanoma in situ on nonchronically sun-exposed skin using 5-mm surgical margins
- Arianna Welch, Taylor Reid, Judith Knox, Morgan L. Wilson
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?